Pharma Focus Europe

Epimab Biotherapeutics and Almirall Announce a License Agreement for Bispecific Antibodies

Saturday, October 14, 2023

EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in the development of multispecific antibodies, has entered into a license agreement with Almirall, a global biopharmaceutical company focusing on medical dermatology. The agreement pertains to the development of bispecific antibodies for up to three undisclosed target pairs.

According to the terms of this collaboration, Almirall will be granted a license to utilize EpimAb's proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform technology. This license will enable Almirall to create, develop, and commercialize bispecific antibodies, with exclusive global rights. In return, EpimAb is eligible to receive milestone payments, which could total up to $210 million, contingent upon the successful launch and commercial performance of multiple products. EpimAb will also receive royalties on net sales for any commercialized product. Specific financial details of the agreement were not disclosed.

Dr. Chengbin Wu, CEO and founder of EpimAb, expressed their excitement about this partnership, stating, "We are delighted to collaborate with Almirall to expand the application of our FIT-Ig® technology beyond the field of oncology. While we have made significant progress in utilizing our platform technology to develop a distinct portfolio of bispecific antibodies in oncology, the potential of our platform in other areas, such as immunology, remains untapped. We believe Almirall is the ideal partner for this endeavor and look forward to exploring the use of our novel bispecific platform to provide additional treatment options for patients with immune-related disorders."

Karl Ziegelbauer, Executive Vice President of R&D and Chief Scientific Officer at Almirall, emphasized the significance of the agreement, stating, "This collaboration with EpimAb represents an important step forward and exemplifies our commitment to developing new biologics in the dermatology field, ultimately bringing innovation to patients."

EpimAb's FIT-Ig® technology platform is distinctive in that it generates bispecific antibodies using only the fundamental structural components of monoclonal antibodies, without introducing complex modifications. This platform is protected by patents in major markets worldwide. EpimAb has already advanced four bispecific molecules into clinical trials using this technology, demonstrating its potential to rapidly progress drug candidates from conception to development.

 

Source: businesswire.com

 

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva